Compare Comfort Systems USA Inc (FIX) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Moderna, Inc. — how do they compare? Comfort Systems USA Inc trades at $1,728.54 (market cap $61.29B), while Moderna, Inc. trades at $196.71 (market cap $78.44B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Comfort Systems USA Inc pays a 0.21% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Comfort Systems USA Inc for 41 Days and Moderna, Inc. for 59 Days on average.
| FIX | MRNA | |
|---|---|---|
Market Cap | $61.29B | $78.44B |
Volume | 365,637 | 14,597,511 |
Sector | Industrials | Health |
52-Week High | $2.07K | $203.46 |
52-Week Low | $790.72 | $22.36 |
Typical Hold Time | 41 Days | 59 Days |
Enterprise Value | $59.76B | $74.59B |
Dividend Yield | 0.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,741.36, down 4.21% today but maintains strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with revenue growth from $9.1B in 2025 to $11.2B projected for 2026, supported by consistent earnings beats and a 55.29% ROE. Recent acquisition of Hunt Electric adds $250M in annual revenue, positioning FIX to capitalize on data center and infrastructure demand.
Outlook remains positive with analyst consensus at Buy (55.56%) and $2,080 price target representing 19% upside. Key risks include execution of growing project backlog and sensitivity to construction cycle fluctuations. The stock's premium valuation (P/E 42.86) requires sustained high growth to justify current levels amid competitive market conditions.
Moderna (MRNA) trades at $197.00, up 5.09% today, with a bullish technical signal supported by moving averages. Recent inclusion in the Nasdaq-100 index has driven positive momentum, though the stock faces valuation concerns after a 500% rally in 2026. Financially, revenue has declined from $18.9B in 2022 to $1.92B in 2025, with net losses widening to -$2.82B. Earnings have consistently beaten expectations, but profitability metrics remain negative.
Outlook: Near-term upside may be capped by high valuations and profit-taking pressure, but long-term growth potential exists in the oncology pipeline. Key risks include sustained revenue declines, competitive threats, and reliance on pipeline success. Analysts are mixed, with a consensus price target of $115.70 suggesting caution despite bullish technicals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
